연구동향 분석
박사

부신피질자극호르몬 분비 뇌하수체 선종 세포주에서 sodium metaarsenite의 효과에 대한 연구 : 쿠싱병 치료제로서의 가능성 = In vitro Effect of Sodium Metaarsenite in ACTH-Secreting Pituitary Adenoma Cells as a Candidate for Treatment of Cushings disease

박정환 2015년

논문상세정보
    • 저자 박정환
    • 형태사항 26 cm: 41 p.: 삽도
    • 일반주기 권두 국문요지, 권말 Abstract 수록, 지도교수: 김동선, 참고문헌: p. 21-29
    • 학위논문사항 2015. 8, 한양대학교 대학원, 학위논문(박사)-, 의학과
    • 발행지 서울
    • 언어 kor
    • 출판년 2015
    • 발행사항 한양대학교 대학원
    • 주제어 의용생체공학
    유사주제 논문( 18)
인용/피인용
' 부신피질자극호르몬 분비 뇌하수체 선종 세포주에서 sodium metaarsenite의 효과에 대한 연구 : 쿠싱병 치료제로서의 가능성 = In vitro Effect of Sodium Metaarsenite in ACTH-Secreting Pituitary Adenoma Cells as a Candidate for Treatment of Cushings disease' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의용생체공학
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
19 0

0.0%

' 부신피질자극호르몬 분비 뇌하수체 선종 세포주에서 sodium metaarsenite의 효과에 대한 연구 : 쿠싱병 치료제로서의 가능성 = In vitro Effect of Sodium Metaarsenite in ACTH-Secreting Pituitary Adenoma Cells as a Candidate for Treatment of Cushings disease' 의 참고문헌

  • de Bruin C, Feelders RA, Lamberts SWJ, Hofland LJ. Somatostatin and dopaminereceptors as targets for medical treatment for Cucing’s Syndrome. Rev Endocr MetabDisord 2009;10:91-102.
  • Zhang P, Wang SY, Hu XH. Arsenuc trioxide treated 72 cases of acute promyelocyticleukemia. Chin J Hematol 1996;17:58-62.
  • Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustractive models. Nat RevCancer 2007;7:35-45.
  • Zatelli MC, Piccin D, Tagliati F, et al. Dopamine receptor subtype 2 andsomatostatin receptor subtype 5 expression influences somatostatin analogs effects on27human somatotroph pituitary adenoma in vitro. J Mol Enodcrinol 2005;35:333-341.
  • Yoon JS, Kim ES, Park BB, et al. Anti-leukemic effect of sodium metaarsenite(KML001) in acute myeloid leukemia with breaking-down the resistance of cytosinearabinoside. Int J Oncol. 2015;46(5):1953-1962.
  • Ye J, Li A, Liu Q, et al. Inhibition of mitogen-activated protein kinase kinaseenhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol 2005;32:1042-1048.
  • Wondisford FE. A new medical therapy for Cushing disease? J Clin Invest2011;121:4621-4623.
  • Wen J, Cheng HY, Feng Y, et al. p38 MAPK inhibition enhancing ATO-inducedcytotoxicity against multiple myeloma cells. Br J Haematol 2008;140(2):169?180.
  • Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming andtransactivation activity. J Biol Chem 2000l275:7459-7461.
  • Wagenmarkers MA, Netea-Maier RT, van Lindert EJ, et al. Repeatedtranssphenoidal pituitary surgery (TS) via the endoscopic technique: a goodtherapeutic option for recurrent or persistent Cushing’s disease (CD). Clin Endocrinol25(Oxf) 2009;70:274-280.
  • Vik-Mo EO, ksnes M, Pedersen PH, et al. Gamma knife stereotactic radiosurgeryof Nelson syndrome. Eur J Endocrinol 2009;160:143-148.
  • Vance ML. Cushing’s disease: radiation therapy. Pituitary 2009;12:11-14.
  • Tritos NA, Biller BMK, Swearingen B. Management of Cushing disease. Nat RevEndocrinol 2011;7:279-289.
  • Tamguney T, Stokoe D. New insight into PTEN. J Cell Sci 2007;120:4071-4079.
  • Tabellini G, Cappellini A, Tazzari PL, et al. Phosphoinositide 3-kinase/Aktinvolvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol2005;202(2):623?634.
  • Sundaram NK, Carluccio A, Geer EB. Characterization of persistent and recurrentCushing’s disease. Pituitary 2014;17:381-391.
  • Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol MetabClin North Am 1999;28:211-222.
  • Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acutepromyelocytic leukemia with arsenic trioxide. N Eng J Med 1998;339:1341-1348.
  • Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide(As2O3) in the treatment ofacute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics inrelapsed patients. Blood 1997;89:3354-3360.
  • Sheehan JP, Xu Z, Salveti DJ, Schmitt PJ, Vance ML. Results of gamma knife surgeryfor Cushing’s disease. J Neurosurg 2013;119:1486-1492.
  • Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitaryadenomas: an intermediate review of its safety, efficacy, and role in the neurosurgicaltreatment armamentarium. J Neurosurg 2005;102:678-691.
  • Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatinand dopamine D2 receptors in pituitary adenoma. Mol Cell Endocinol 2008;286:206-213.
  • Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of thePTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet2008;40:102-107.
  • Rutkowski MJ, Flanigan PM, Aghi MK. Update on the management of recurrentCushing’s disease. Neurosurg Focus. 2015;38(2):E16. doi: 10.3171/2014.11.FOCUS14703.
  • Ramos AM, Fernandez C, Amran D, et al. Pharmacologic inhibitors of PI3K/Aktpotentiate the apoptotic action of the antileukemic drug arsenic trioxide viaglutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005;105(10):4013?4020.
  • Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression andfunction in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89:2452-2462.
  • Pinto SS. Henderson V, Enterline PE. Mortality experience of arsenic-exposedworkers. Arch Environ Health. 1978;33(6):325-331.
  • Phatak P, Dai F, Butler M, et al. KML001 cytotoxic activity is associated with itsbinding to telomeric sequences and telomere erosion in prostate cancer cells. ClinCancer Res 2008;14(14):4593-4602.
  • Petit JH, Billaer BMK, Yock TI, et al. Proton stereotactic radiotherapy for persistentadrenocorticotropin-producing adenoma. J Clin Endocrinol Metab 2008;93:393-399.
  • Patil CG, Veeravagu A, Prevedello DM, et al. Outcomes after repeat transshenidalsurgery for recurrent Cushing’s disease. Eurosurgery 2008;63:266-271.
  • Oβwald A, Plomer E, Dimopoulou C, et al. Favorable long-term outcomes ofbilateral adrenalectomy in Cushing’s disease. Eur J Endocrinol 2014;171:209-215.
  • Murasawa S, Kageyama K, Sugiyama A, et al. Inhibitory effects of SOM230 onadrenocorticotropic hormone production and corticotroph tumor cell proliferation invitro and in vivo. Mol Cell Endocrinol 2014;394:37-46.
  • Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. BiochimBiophys Acta 2003;1616:1-84.
  • Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62(14):3893-3903.
  • McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathwayin cell growth, malignant transformation and drug resistance. Biochim Biophys Acta2007;1773:1263-1284.
  • Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in thetreatment of newly diagnosed acute promyelocytic leukemia: durable remissions withminimal toxicity. Blood 2006;107(7):2627-2632.
  • Marek J, Je?kova J, Hana V, et al. Gamma knife radiosurgery for Cushing’s diseaseand Nelson’s syndrome. Pituitary 2015;18:376-384.
  • Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acutemyelogenous leukemia to arsenic trioxide-induced apoptosis. Blood2006;107(11):4549?4553.
  • Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary radiotherapy forCushing’s disease. Neuroensdocrinology 2010;92 Suppl 1:107-110
  • Liubinas SV, Porto LD, Kaye AH. Management of recurrent Cushing’s disease. J ClinNeurosci 2011;18:7-12.
  • Kobayashi T. Long-term results of stereotactic gamma knife radiosurgery forpituitary adenomas. Specific strategies for different types if adenoma. Prog NeurolSurg 2009;22:77-95.
  • Knappe UJ, Ludecke DK. Persistent and recurrent hypercortisolism aftertransshpenoidal surgery for Cushing’s disease. Acta Neurochir Suppl 1996;65:31-34.
  • Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxideselectively induces acute promyelocytic leukemia cell apoptosis via a hydrogenperoxidase-dependent pathway. Blood 1999;94(6):2102-2111.
  • Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma knife surgery for Cushing’sdisease. J Neurosurg 2007;106:980-987.
  • Hofmann BM, Hlavac M, Martinez R, et al. Long-term reslts after microsurgery forCushing disease: experience with 426 primary operations over 35 years. J Neurosurg2008;108:9-18.
  • Hofland LJ, Lamberts SW, Feelders RA. Role of somatostatin receptors in normaland tumoral pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol2005;153:143-151.
  • Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery forCushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab2004;89:6348-6357.
  • Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. JEndocrinol 2005;184:11-28.
  • Ghostine S, Ghostine MS, Johnson WD. Radiation therapy in the treatment ofpituitary tumors. Neurosurg Focus 2008;24(5):E8.
  • Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target forhuman, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest2011;121:4712-4721.
  • Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenousleukemia. JAMA 1931;97:3-5.
  • Fleseriu M, Biller BMK, Findling JW, et al. Mefepristone, a glucocorticoid receptorantagonist, produces clinical and metabolic benefits in patients with Cushing’ssyndrome. J Clin Endocrinol Metab 2012;97:2039-2049.
  • Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivosomatotropic adenoma responsiveness to somatostatin analogs and dopamineagonists with immunohistorchemical evaluation of somatostatin and dopaminereceptors and electron microscopy. J Clin Endocrinol Metab 2008;93:1412-1417.
  • Ferone D, Gatto F, Arvigo M, et al. The clinical-molecular interface of somatostatin,dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol2009;42:361-370.
  • Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitaryirradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl JMed 1997;336:172-177.
  • Eguchi R, Fujimori Y, Takeda H, et al. Arsenic trioxide induces apoptosis throughJNK and ERK in human mesothelioma cells. J Cell Physiol 2011;226:762-768.
  • Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK andPI3K/AKT/mTOR pathway in pituitary adenoma and their effects on downstreameffectors. Endocr Relat Cancer 2009;16:1329-1338.
  • Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumors. Eur J Clin Invest 2012;42:665-676.
  • Dong JT, Luo XM. Effects of arsenic on DNA damage and repair in human fetal lungfibroblasts. Mutat Res. 1994;315(1):11-15.
  • Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas byfractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J RadiatOncol Biol Phys 2005;62:333-341.
  • Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study ofpasireotide in Cushing’s disease. N Engl J Med 2012;366:914-924.
  • Chou Wc, Hawkins AL, Barret JF, Griffin CA, Dang CV. Arsenic inhibition oftelomerase transcription leads to genetic instability. J Clin Invest 2001;108(10):1541-1547.
  • Chesnokova V, Zonis S, Zhou C, et al. Lineage-specific restraint of pituitarygonadotroph cell adenoma growth. PLoS ONE 2011;6,e1724. doi:10.1371/journal.pone.0017924.
  • Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3activation in arsenite-induced apoptosis. J Cell Physiol 1998;177(2):324-333.
  • Chee GH, Mathias DBm, James RA, Kendall-Taylor P. Transsphenoidal pituitarysurgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf)2001;54:617-626.
  • Chamaon K, Kirches E, Kanakis D, et al. Regulation of the pituitary tumortransforming gene by insulin-like-growth factor-I and insulin differs betweenmalignant and non-neoplastic astrocytes. Biochem Biophys Res Commun 2005;331:86-92.
  • Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: apreoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol2008;158:91-99.
  • Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev2001;22:724-763.
  • Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-termremission rates after pituitary surgery for Cushing’s disease: the need for long-termsurveillance. Clin Endocrinol (Oxf) 2005;63:549-559.
  • Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001;6 Suppl 2:1-2.
  • Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin PractEndocrinol Metab 2008;4:560-568.
  • Aghi MK, Petit J, Chapman P, et al. Management of recurrent and refractoryCushing’s disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg2008;55:141-144.